Prostatitis

Researchers are studying men with metastatic castration-resistant prostate cancer mCRPC to understand how different PETCT scans can predict outcomes during radioligand therapy with 177Lu-PSMA-617. This is an exploratory, prospective study conducted at a single center, focusing on imaging tumor heterogeneity to help assess therapy effects and patient response. The study is designed specifically for Veterans undergoing this treatment. Participants will receive several types of PETCT scans at different times before starting LuPSMA radioligand therapy RLT, and then after the 2nd, 4th, and 6th treatment cycles. These scans include 18F-Fluciclovine PETCT Axumin, 18F-DCFPyL PETCT, and 18F-FDG PETCT. The 18F-Fluciclovine scans will be performed within seven days of the PSMA PET scans to compare imaging results at each time point. During the study, detailed imaging measures such as lesion uptake and tumor volume will be collected and analyzed over time. Patients will be followed at the institution to correlate these imaging results with clinical outcomes. The main outcome measured is the impact of 18F-Fluciclovine PETCT on predicting outcomes of the 177Lu-PSMA-617 therapy from enrollment through 34 weeks of treatment.

Researchers are investigating why some men with Benign Prostatic Hyperplasia BPH, a common condition causing urinary problems due to prostate enlargement, do not respond to the typical treatment drug Finasteride. The study focuses on understanding resistance to this treatment and hopes to use noninvasive methods like MRI to detect prostate inflammation and predict which patients will not benefit from Finasteride, allowing for alternative treatments in the future. Men eligible for the study will receive Finasteride as standard care for BPH symptoms, particularly those with moderate urinary symptoms and a prostate size over 40cc. Participants will undergo prostate MRIs and biopsies, along with blood and urine tests, before starting treatment. They will be monitored every six months with symptom assessments and have follow-up MRIs at three years to track changes in prostate size and inflammation, while tissue samples will be analyzed for gene expression and hormonal levels. Throughout the study, participants will attend clinic visits to evaluate urinary symptoms and treatment response, with a key assessment at 12 months to measure the effect of Finasteride. Researchers will collect detailed data including MRI scans, prostate tissue analyses, and hormone tests to understand treatment resistance. The study aims to improve how BPH is managed by identifying patients unlikely to respond to current therapy, with monitoring continuing over several years to gather comprehensive information.

Prostate cancer is the most common cancer among men in Denmark, often developing slowly without symptoms. This trial evaluates a complex intervention designed to improve how general practitioners GPs use prostate specific antigen PSA tests in line with national guidelines. The goal is to reduce overdiagnosis and overtreatment caused by unnecessary PSA testing, by promoting evidence-based practice among GPs in quality clusters. The intervention involves a cluster package including a pre-recorded podcast for GPs, a two-hour cluster meeting with educational material and group discussions, and two sets of hand-outs to support GPs in their clinics. Quality clusters are randomized to either receive this intervention over six months or act as a control group, which will be offered the intervention afterward. Participants, who are quality clusters of GPs, will be involved in cluster meetings and use the provided materials. Researchers will measure changes in PSA testing frequency among men during the six-month intervention period, as well as variations between GPs. The study includes assessments of PSA test use before and after the intervention to evaluate its impact on clinical practice.

Researchers are evaluating the safety and effects of FX-111 in adult men with metastatic castration-resistant prostate cancer mCRPC. This phase 1 trial aims to understand the side effects of FX-111, how the body processes the drug, and whether FX-111 helps reduce or prevent the progression of mCRPC. The study focuses on men whose prostate cancer has advanced despite hormone therapy. Participants will take FX-111 orally once daily in continuous 28-day cycles. The study includes several dose levels of FX-111 to evaluate its safety and effects. Treatment will continue with regular monitoring for about six months. During this time, researchers will assess drug concentrations in the blood and measure PSA levels and tumor responses at scheduled intervals. Participants will have frequent physical exams and laboratory tests to monitor health and tumor status. PSA levels will be checked every four weeks, and tumor assessments will be done every eight weeks throughout the study. The main outcomes include tracking adverse events and how well the drug controls cancer growth. Participants will be followed for approximately six months to evaluate treatment effects and safety under medical supervision.

Researchers are conducting an international, multicenter observational study to understand how patients admitted to hospitals with emergency haematuria are managed. The study aims to identify variations in care, measure outcomes like length of hospital stay, mortality, readmission rates, and resource use, and support the development of future guidelines and trials to improve haematuria management. The study collects detailed data on patient demographics, underlying health conditions, diagnostic procedures, treatments, and outcomes using a standardized form. It includes patients admitted as emergencies with haematuria under urology care. The study observes current hospital management pathways and gathers information through questionnaires to participating sites. Participants will be followed during their hospital stay and for 90 days afterward. Researchers will evaluate length of stay, time to diagnosis, mortality at 30 and 90 days, readmissions, days alive and out of hospital, and healthcare costs. The study uses data analysis to assess factors linked to outcomes and variations in care. Participation involves no changes to treatment as it is observational, and data will be collected consecutively over a 12-month period from multiple centers.

Researchers are evaluating a new way to provide preoperative information to patients who are candidates for spinal or urological surgery. This study is an interventional, randomized controlled trial conducted at multiple centers. It aims to compare a new multimedia-based method that objectively checks patient understanding against the standard informed consent process to see which better supports patient decision-making about surgery. Participants in the experimental group will receive detailed information through videos with surgical options, graphics, and animations. They will also have interviews with the surgeon and caregivers using 3D-printed models to guide shared decision-making. After deciding on surgery, patients will join educational programs to reinforce understanding before a final surgeon interview and signing of informed consent. The control group will receive the usual care, including a standard explanatory interview and consent signing. Throughout the study, participants will complete questionnaires assessing satisfaction, comprehension, mental health, pain, disability, urinary and sexual function, and legal outcomes at multiple time points before surgery, at discharge, and at two and six months after surgery. The research team will monitor these measures to evaluate the impact of the new method on patient understanding and decision satisfaction over time.

Researchers are developing and managing the AnovaOS Network Powered Patient Registry to collect real-world patient data across various diseases globally. This registry aims to capture meaningful clinical information on diagnosis, infection course, treatments, and outcomes to enhance understanding and support future clinical trials and observational studies. The registry serves as a resource to better understand, prevent, diagnose, and treat diverse health conditions. Participants data will be gathered through this registry, which can also be used to recruit individuals for clinical trials and observational studies on promising therapies. The registry collects ongoing information on patients health status and treatments, enabling long-term monitoring and analysis. This observational study does not involve administering treatments but focuses on data collection and management. Participants will provide information through questionnaires or instruments, either personally or via an informed proxy, with an expected follow-up once per year. The research team will assess natural history, clinical effectiveness, safety, and quality of care over a period of five years. The registry includes patients with a wide range of conditions, and participation requires informed consent and the ability to complete follow-up data collection.

Prostate cancer is the most commonly diagnosed cancer in men in the United States. Many men undergo prostate biopsy due to elevated prostate-specific antigen PSA levels, but often no cancer is found. Elevated PSA levels can result from inflammation, benign prostate enlargement, infections, or natural variations. This research aims to study whether over-the-counter anti-inflammatory drugs like ibuprofen or naproxen can lower PSA levels and potentially reduce unnecessary biopsies. Participants are randomly assigned to one of two groups. One group will have a repeat PSA test after about 6 weeks without treatment, while the other group will take ibuprofen 400 mg three times daily for 10 days before repeating the PSA test at around 6 weeks. The study compares changes in PSA levels between these groups to understand the effect of anti-inflammatory medications. During the study, participants will have PSA tests, and their symptoms will be monitored using questionnaires like the International Prostate Symptom Score over 3 to 12 months. Researchers will track kidney function to identify any risks from ibuprofen use and assess how long any changes in PSA levels last up to 1.5 years. The goal is to identify safer ways to manage elevated PSA levels and avoid unnecessary procedures. Total participation may extend up to a year or more for follow-up assessments.

Researchers are studying Lutetium 177Lu rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer mCRPC that expresses prostate-specific membrane antigen PSMA. This open-label Phase 1 and 2 study aims to determine the appropriate dose, safety, radiation exposure, and anti-tumor activity of this treatment. Participants include men whose cancer has progressed despite prior therapies, with Phase 1 focusing on those who had chemotherapy and Phase 2 on those who have not received taxane chemotherapy. Participants will receive different dosing regimens of 177Lu-rhPSMA-10.1 based on their study group. Doses vary from 5.55GBq to 14.80GBq, administered in up to 8 cycles at intervals of 3 to 6 weeks. Phase 1 includes dose-finding, safety, and radiation dosimetry assessments, while Phase 2 evaluates efficacy and safety of the dosing schedules chosen from Phase 1. A PETCT scan using 18F-rhPSMA-7.3 is used in Phase 1 to confirm PSMA-positive disease. During the study, participants will undergo regular monitoring including imaging scans, blood tests, and assessments of treatment side effects. Researchers will track dose-limiting toxicities, treatment-emergent adverse events, and efficacy measured at six-week intervals. Participants will be observed up to six weeks after their final dose for safety. The study duration and follow-up depend on treatment cycles and individual response, with ongoing evaluation of radiation dosage and anti-tumor effects.

Researchers are evaluating Aquablation therapy, a robotically executed, surgeon-guided high-pressure water jet procedure, for men with benign prostatic hyperplasia BPH in a Canadian patient group. The goal is to document the clinical outcomes of this treatment for BPH, a condition involving prostate enlargement that affects urinary function. Patients will be followed as part of standard care for up to three years to gather data on the therapys effects. The study focuses on Aquablation as the primary intervention, which involves endoscopic resection of prostate tissue using high-pressure water jets guided by robotic technology and a surgeon. There are no comparison groups mentioned, as this is an observational study documenting outcomes after Aquablation therapy. The treatment is delivered once, and patients are monitored over time to assess changes. Participants will be evaluated at multiple points including baseline, 1 month, 3 months, 6 months, 12 months, 24 months, and 36 months after surgery. Assessments include maximum urine flow rate Q-max, post-void residual PVR urine volume, prostate volume, patient questionnaires, and monitoring for adverse events. Follow-up visits align with routine care to track the therapys impact and safety over three years.